Illumina Inc (ILMN) Files Form 4 Insider Selling : A Blaine Bowman Sells 5,000 Shares

Illumina Inc (ILMN): A Blaine Bowman , director of Illumina Inc sold 5,000 shares on May 12, 2016. The Insider selling transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were sold at $137.63 per share for a total value of $685,535.19 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 28, 2016, Christian O Henry (EVP & Chief Commercial Officer) sold 2,141 shares at $138.53 per share price.On Apr 20, 2016, Paul L Bianchi (Sr. VP, Human Resources) sold 1,884 shares at $175.00 per share price.Also, On Apr 15, 2016, A Blaine Bowman (director) sold 5,000 shares at $172.96 per share price.On Apr 14, 2016, Jay T Flatley (Chief Executive Officer) sold 20,000 shares at $170.14 per share price.

Illumina: On Tuesday, May 10, 2016 heightened volatility was witnessed in Illumina which led to swings in the share price. The shares opened for trading at $142.41 and hit $142.995 on the upside , eventually ending the session at $142.84, with a gain of 0.76% or 1.08 points. The heightened volatility saw the trading volume jump to 7,92,146 shares. The 52-week high of the share price is $242.37 and the company has a market cap of $21,026 M . The 52-week low of the share price is at $127.1.

Illumina Money Flow Index Chart

Company has been under the radar of several Street Analysts.Illumina is Reiterated by Mizuho to Neutral while Lowering the Price Target of the company shares to $ 138 from a previous price target of $150 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Stifel to Buy while Lowering the Price Target of the company shares to $ 160 from a previous price target of $215 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Canaccord Genuity to Hold while Lowering the Price Target of the company shares to $ 140 from a previous price target of $160 . The Rating was issued on May 4, 2016.Illumina is Reiterated by Morgan Stanley to Overweight while Lowering the Price Target of the company shares to $ 130 from a previous price target of $140 . The Rating was issued on May 3, 2016.Illumina is Reiterated by UBS to Buy while Lowering the Price Target of the company shares to $ 180 from a previous price target of $210 . The Rating was issued on May 3, 2016.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.